Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

The Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research program is a federal funding opportunity issued by the National Institutes of Health within the U.S. Department of Health and Human Services, specifically through the National Cancer Institute. This program is part of the Innovative Molecular Analysis Technologies initiative, which focuses on advancing cancer research through the development of novel tools and methods. The opportunity is structured as a discretionary grant mechanism and is designed to support early-stage, high-risk, high-reward technology development efforts that may significantly enhance the study and treatment of cancer. The primary purpose of this funding opportunity is to stimulate the creation and validation of innovative technologies that can accelerate progress in cancer research and clinical care. Projects supported under this program are expected to focus on proof-of-concept or pilot studies that demonstrate the technical feasibility of new methods, tools, assays, platforms, or instruments. These technologies must exhibit a high degree of innovation and have the potential to improve research capabilities across areas such as cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and epidemiology. The emphasis is on transformative approaches rather than incremental improvements. Eligible projects may involve a wide range of technological domains, including advanced molecular and cellular analysis platforms, multi-omic and spatial profiling techniques, imaging and sensing technologies, immuno-engineering innovations, and improved methods for biospecimen processing and modeling. While the technologies developed may have broader applications, they must be clearly focused on cancer-related use cases within the scope of the proposal. Funding is intended to support early-stage development activities rather than fully mature or late-stage technologies. The program does not require cost sharing or matching contributions, which lowers barriers to entry for a diverse set of applicants. Eligible applicants include a broad array of entity types such as academic institutions, nonprofits, small businesses, government entities at various levels, tribal organizations, and certain international institutions. This inclusive eligibility framework reflects the program’s goal of fostering innovation across sectors and disciplines. Applications are expected to be submitted following the official release of the funding opportunity, with an estimated posting date of January 15, 2027. The anticipated application deadline is June 4, 2027. Applicants must prepare and submit detailed proposals outlining the proposed technology, its innovative aspects, feasibility testing plans, and potential impact on cancer research or clinical care. While specific application components are not detailed in the forecast, standard NIH submission requirements are expected to apply, including research plans, budgets, and institutional information. The evaluation process will likely focus on the degree of innovation, technical feasibility, scientific merit, and potential impact of the proposed technology. Applications that demonstrate strong potential to significantly enhance cancer research capabilities or clinical outcomes will be prioritized. The program anticipates making approximately 23 awards, with funding decisions expected around April 1, 2028, and project start dates projected for April 15, 2028. For inquiries, applicants may contact the IMAT Program at the National Cancer Institute via email or phone. The program is part of an ongoing federal research funding ecosystem, and while this specific opportunity is forecasted, similar opportunities may recur in future cycles as part of the broader IMAT initiative. Applicants are encouraged to monitor updates and prepare early for submission once the opportunity officially opens.

Emphasize high technical innovation and clear demonstration of feasibility with strong relevance to cancer research applications